Compare
Northwest Biotherapeutics Inc vs Cannapharmarx, Inc. vs IGC Pharma, Inc. vs Vistagen Therapeutics, Inc.
| Latest fiscal year | Northwest Biotherapeutics Inc NWBO | Cannapharmarx, Inc. CPMD | IGC Pharma, Inc. IGCLast annual report: year ended 2025-03-31 | Vistagen Therapeutics, Inc. VTGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-03-31 | 2026-03-31 |
| Revenue | $1.38M | $1.36M | $1.27M | $1.27M |
| Revenue growth (YoY) | -0.3% | +66.1% | -5.5% | +161.1% |
| Gross margin | n/a | -153.1% | 48.7% | n/a |
| Operating margin | n/m | -245.8% | -585.8% | n/m |
| Net margin | n/m | -817.2% | -560.3% | n/m |
| Net income | -$60.16M | -$11.13M | -$7.12M | -$69.69M |
| EPS (Diluted) | -$0.04 | -$0.02 | -$0.09 | -$1.83 |
| Operating cash flow | -$44.76M | -$789.1K | -$4.79M | -$66.44M |
| Free cash flow | -$46.27M | -$794.6K | -$4.91M | n/a |
| Cash & equivalents | $3.04M | $1.8K | $405.0K | $30.79M |
| Total assets | $81.29M | $7.02M | $8.75M | $48.56M |
| Total liabilities | $128.86M | $37.17M | $2.42M | $13.04M |
| Shareholders' equity | -$60.28M | -$30.15M | $6.33M | $35.52M |
| Return on year-end equity | n/a | n/a | -112.5% | -196.2% |
| Shares outstanding | 1.56B | 662.50M | 80.88M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Northwest Biotherapeutics Inc | Cannapharmarx, Inc. | IGC Pharma, Inc. | Vistagen Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.38M Ended 2025-12-31 | $1.36M Ended 2025-12-31 | $1.27M Ended 2025-03-31 | $1.27M Ended 2026-03-31 |
| 1 year earlier | $1.38M Ended 2024-12-31 | $820.1K Ended 2024-12-31 | $1.34M Ended 2024-03-31 | $486.0K Ended 2025-03-31 |
| 2 years earlier | $1.93M Ended 2023-12-31 | $0 Ended 2023-12-31 | $911.0K Ended 2023-03-31 | $1.06M Ended 2024-03-31 |
| 3 years earlier | $1.68M Ended 2022-12-31 | $0 Ended 2022-12-31 | $397.0K Ended 2022-03-31 | n/a |
| 4 years earlier | $1.00M Ended 2021-12-31 | $0 Ended 2021-12-31 | $898.0K Ended 2021-03-31 | $1.11M Ended 2022-03-31 |